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Abstract
Background: Our aim was to investigate patterns of health care resource use by patients before and after a
diagnosis of CFS/ME, as recorded by Clinical Practice Research Datalink (CPRD) GP practices in the UK.
Methods: We used a case–control study design in which patients who had a first recorded diagnosis of CFS/ME
during the period 01/01/2001 to 31/12/2013 were matched 1:1 with controls by age, sex, and GP practice. We
compared rates of GP consultations, diagnostic tests, prescriptions, referrals, and symptoms between the two
groups from 15 years (in adults) or 10 years (in children) before diagnosis to 10 years after diagnosis.
Results: Data were available for 6710 adult and 916 child (age <18 years) matched case–control pairs. Rates of GP
consultations, diagnostic tests, prescriptions, referrals, and symptoms spiked dramatically in the year when a CFS/ME
diagnosis was recorded. GP consultation rates were 50% higher in adult cases compared to controls 11–15 years before
diagnosis (rate ratio (RR) 1.49 (95% CI 1.46, 1.52)) and 56% higher 6–10 years after diagnosis (RR 1.56 (1.54, 1.57)). In
children, consultation rates in cases were 45% higher 6–10 years before diagnosis (RR 1.45 (1.40, 1.51)) and 62% higher 6–
10 years after diagnosis (RR 1.62 (1.54, 1.70)). For adults and children, rates of tests, prescriptions, referrals, and symptoms
were higher in cases compared to controls for up to 10 years before and after diagnosis.
Conclusions: Adults and children with CFS/ME have greater health care needs than the rest of the population for at least
ten years before their diagnosis, and these higher levels of health care resource use continue for at least ten years after
diagnosis.
Keywords: Chronic fatigue syndrome, CFS/ME, fibromyalgia, Diagnosis, Adults, Children, Primary care, CPRD, Health care
resource use
Background
Chronic fatigue syndrome (CFS, also known as ‘ME’) is a
debilitating illness of unknown aetiology and pathophysi-
ology [1]. Characterizing patients’ long-term health status
before and after the onset and diagnosis of CFS/ME is im-
portant if we are to quantify the health economic and so-
cietal costs of CFS/ME, and the effects of diagnosis on
health care use. Productivity losses due to CFS/ME in the
UK have been estimated to be more than £100 M per
annum [2]. These estimates of indirect costs were based
on self-reported duration of illness (median 3 years)
among patients who were able to access specialist CFS/
ME services and who do not include all patients with
CFS/ME. Direct costs of CFS/ME have been estimated
from health care resource use by patients presenting to
GPs in England, but only for short periods (3–6 months)
prior to diagnosis [3, 4].
The aim of our study was to investigate long-term pat-
terns in health care resource use before and after a diag-
nosis of CFS/ME using data from the Clinical Practice
Research Datalink (CPRD). The CPRD provides data
from approximately 7% of primary care (GP) practices in
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the UK [5]. We hypothesised that health care resource
use would increase from around the time of patient-
reported onset of illness (median self-reported duration
of illness among patients who attend NHS specialist ser-
vices is 3 years (adults), 16 months (children age 12–18
years) and 12 months (children <12 years old)) [1] until
diagnosis. We did not have a prior hypothesis about
post-diagnosis health care resource use, although this
might be expected to fall if diagnosis led to referral and
effective treatment. We also investigated whether health
care resource use varied by sex and by socioeconomic
status, given earlier evidence of a social gradient in ac-
cess to CFS/ME specialist services in England [6] and in
incidence of CFS/ME diagnoses [7], and we investigated
adult and paediatric patients, given differences in pres-
entation and prognosis [1].
Methods
Data source
The Clinical Practice Research Datalink (CPRD),
formerly known as the General Practice Research Data-
base (GPRD), is an anonymised research database aggre-
gating medical records data from participating general
practices across the UK (approximately 7% of 10,000
practices in 2012) [5]. Practices contributing to CPRD
are broadly representative of general practices in the UK
in terms of practice size and geographical distribution,
and the source population (approximately four million
‘active’ patients, i.e. alive and registered with a GP) is
broadly representative of the population of the UK in
terms of age, sex, and ethnicity. GPs enter medical diag-
noses and symptoms as Read codes, a hierarchical cod-
ing system used to record clinical information.
Procedures, prescriptions, and referrals to secondary
care are also recorded. CPRD provides two sets of data
quality criteria: ‘up-to-standard’ (UTS) date for practices
and ‘acceptability’ for patients [5]. These criteria do not
ensure data quality, but they are used to delineate pe-
riods of quality data recording. UTS date is the date
from which data in the practice are considered to be of
sufficiently high quality by checking that events are be-
ing recorded continually and that recording of deaths
matches projections for the practice (allowing for geo-
graphical and seasonal variation). For this study, data re-
corded since the practice UTS date were obtained from
660 general practices in the UK from 01/01/2001 to 31/
12/2013. The acceptable patient metric is based on
registration status, consistency and completeness of re-
cording of events in the patient record, and valid infor-
mation on age and sex [5]. Patients with non-contiguous
records or poor data recording, which thereby raises
suspicion about the validity of that patient’s record, are
excluded. This study used the medical record data of pa-
tients who had acceptable data from a period beginning
with the latest of the patient’s current registration period
and the practice UTS date, and ending with the earliest
of the patient’s transfer out date, the practice last collec-
tion date and the study end date.
Cases
Cases were patients who had a new diagnosis of CFS/
ME during the study period (01/01/2001 to 31/12/2013),
as indicated by an index event with a Read code for
diagnosis of CFS/ME (nine possible Read codes [8]) or
referral to a CFS/ME specialist service (Additional file 1:
Table S1). We considered new CFS/ME diagnoses to be
those index events for which there was no preceding
diagnosis of CFS/ME, FM, PVFS or asthenia/debility in
the patient’s CPRD medical record as indicated by prior
events with the corresponding Read codes (Additional
file 1: Table S1). Read codes for referral to specialist ser-
vices were introduced in 2010. Diagnoses which were
made after a referral (and for which there was no prior
diagnosis) were treated as new diagnoses.
Controls
For each case, one control was matched on index event
date, practice, year of birth, and sex. Controls were se-
lected at random from patients who had no recorded
diagnosis of CFS/ME, post-viral fatigue syndrome, asthe-
nia/debility or fibromyalgia. Matching on index event
date meant that the index event of the case must have
occurred within the control’s registration period.
Health care resource use
GP consultations, tests, prescriptions, and referrals were
counted if they had been recorded in the patient’s med-
ical record at any time during the patient’s current regis-
tration period with the primary care practice. Multiple
GP consultations on one day were counted as a single
consultation. Multiple tests per day were counted in
order to reflect the total number of tests ordered. Mul-
tiple prescriptions per day were counted, but only new
prescriptions were included, i.e. repeat (recurring) pre-
scriptions were not counted. Cases and controls were re-
quired to have at least 12 months of UTS and acceptable
data prior to the index event date, in order to avoid the
excess events which tend to occur shortly after a patient
has registered with a practice [9].
Symptoms
Symptoms were flagged as ‘all’ symptoms, i.e. a symptom
of any type, and ‘fatigue’ symptoms (if the symptom had
a Read code as listed in Additional file 1: Table S1).
Practice-level socioeconomic status
Index of Multiple Deprivation (IMD) score was used as a
measure of socioeconomic status for the practice, based
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on its postcode. The IMD is the UK government’s official
measure of deprivation.[10] It is a composite score derived
from seven domains: income, employment, health and dis-
ability, education skills and training, barriers to housing
and services, crime and disorder, and living environment.
We grouped the top three (least deprived) quintiles and
bottom two (most deprived) quintiles into two IMD strata
to simplify our analysis and because our study of trends in
CFS/ME diagnoses using CPRD data had shown a differ-
ence in incidence rates across these groupings [7].
Statistical analyses
Annual rates (and 95% confidence intervals (CIs)) per
patient of health care resource use events and symp-
toms were calculated by summing the number of
events during each calendar year (for up to 15 years
before and up to 10 years after the year of first re-
corded diagnosis of CFS/ME), and dividing by the
number of patients whose medical data extended up
until that time. We calculated rate ratios for cases com-
pared with controls by fitting negative binomial regression
models including a term for interaction between case sta-
tus and time period, coded as three 5-year periods pre-
diagnosis (11–15, 6–10 and 1–5 years before diagnosis),
year of diagnosis (year 0), and two 5-year periods post-
diagnosis (1–5 and 6–10 years). This allowed us to esti-
mate the mean ratio between rates for cases compared
with controls during each time period. Models were fitted
using Stata (StataCorp. 2015. Stata Statistical Software:
Release 14. College Station, TX: StataCorp LP).
Results
Study population
7901 patients had a new CFS/ME diagnosis recorded
during the study period. Matched controls were available
for 7626 (96.5%) of these patients. The population com-
prised 916 child (age <18 years) and 6710 adult patients.
At the time of the index event, the median (interquartile
range (IQR)) age of child patients was 15 (13–16) years,
and 63.9% (585/916) were female; the median (IQR) age
of adult patients was 43 (33–53) years, and 72.6% (4874/
6710) were female.
The durations of pre-diagnosis data were the same in
cases and controls, with a median (IQR) of 6 (3–11)
years for both adult cases and controls, 8 (4–12) years
for child cases, and 8 (4–11) years for child controls.
Post-diagnosis data were available for 5 (3–9) years for
adult cases, 5 (2–8) years for adult controls, and 4 (2–7)
years for both child cases and controls. Up to 10 years of
pre-diagnosis data were available for 25.9% (1737/6710)
and 26.0% (1744/6710) of adult cases and controls, re-
spectively (Additional file 1: Table S2), and 10 years of
post-diagnosis data were available for 19.8% (1328/6710)
and 18.4% (1232/6710) of adult cases and controls. Ten
years of pre-diagnosis data were available for 32.3%
(296/916) and 31.0% (284/916) of child cases and con-
trols (Additional file 1: Table S3), and post-diagnosis
data up to 10 years were available for 11.7% (107/916)
and 12.1% (111/916). Fifteen years of pre-diagnosis data
were available for 7.6% (509/6710) and 7.9% (529/6710)
of adult cases and controls, respectively.
Health care resource use
Adults
At 11–15 years before their first recorded CFS/ME diag-
nosis, GP consultations per patient per year were 49%
higher in cases compared with controls (rate ratio (RR)
1.49 (95% CI 1.46, 1.52)) (Table 1, Fig. 1). During the
5 years before diagnosis, the rate of GP consultations
was 76% higher (RR 1.76 (1.75, 1.77)) and, in the year
when the diagnosis was recorded, the rate was 2.5 times
higher (RR 2.48 (2.44, 2.51)). The rate ratio fell steeply
after diagnosis, and was 56% higher (RR 1.56 (1.54,
1.57)) over the period 6–10 years post-diagnosis. Rates
of tests, new prescriptions and referrals were, respect-
ively, 64% (RR 1.64 (1.59, 1.68)), 56% (RR 1.56 (1.53,
1.58)) and 53% (RR 1.53 (1.46, 1.60)) higher in cases
compared with controls at 11–15 years pre-diagnosis
(Table 1, Fig. 1). Rate ratios for tests, prescriptions and
referrals peaked at 3.0, 2.4 and 3.5, respectively, in the
year when a CFS/ME diagnosis was first recorded. At 6–
10 years post-diagnosis, rates of tests, prescriptions and
referrals were, respectively, 50% (RR 1.50 (1.49, 1.51)),
85% (RR 1.85 (1.82, 1.87)) and 78% (RR 1.78 (1.72, 1.85))
higher in cases compared with controls.
Children
At 6–10 years before their first recorded CFS/ME
diagnosis, GP consultations per patient per year were
45% higher in cases compared with controls (RR 1.45
(1.40, 1.51)) (Table 2, Fig. 2). During the 5 years be-
fore diagnosis the rate of GP consultations in cases
was more than double the rate in controls (RR 2.34
(2.28, 2.41)), peaking at a 4-fold higher rate (RR 4.10
(3.90, 4.31)) in the year when the diagnosis was re-
corded. The rate ratio fell steeply after diagnosis, and
was 62% higher (RR 1.62 (1.54, 1.70)) over the period
6–10 years post-diagnosis. Test rates in cases began
almost 3-fold higher than in controls at 6–10 years
pre-diagnosis (RR 2.70 (2.51, 2.89)), peaked at a 13-
fold higher rate (RR 12.9 (12.3, 13.5)) and fell back to
>2 times higher 6–10 years later (RR 2.37 (2.29,
2.44)) (Table 2, Fig. 2). Relative rates of new pres-
criptions were 44% higher 6–10 years pre-diagnosis
(RR 1.44 (1.39, 1.50)), peaking at 3.3 times higher in
the year of diagnosis, and falling back to 84% higher
6–10 years later (RR 1.84 (1.74, 1.93)). Referral rates
were 40% higher at 6–10 years pre-diagnosis (RR 1.40
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(1.22, 1.60)), peaked at a 9-fold higher rate (RR 8.83
(7.38, 10.6)) and were 2.5-fold higher 6–10 years
post-diagnosis (RR 2.53 (2.12, 3.03)).
Symptoms
Adults
Relative rates of all (any) recorded symptoms were 55-69%
higher in cases compared with controls from 6–15 years
pre-diagnosis and 1–10 years post-diagnosis, peaking at a
>2-fold higher rate in the year of diagnosis (RR 2.34 (2.28,
2.39)) (Table 3, Fig. 3, Additional file 1: Table S4). Relative
rates of fatigue symptoms were much higher in cases
compared with controls, rising from an 8-fold higher rate
11–15 years pre-diagnosis (RR 8.12 (4.83, 13.7)) to a 22-
fold higher rate in the year of diagnosis (RR 21.9 (18.8,
25.5)), then falling to a 4-fold higher rate 6–10 years post-
diagnosis (RR 3.75 (3.26, 4.32)).
Children
Symptoms of any kind were recorded at a 68% higher
rate (RR 1.68 (1.57, 1.79)) in child cases compared
with controls 6–10 years before diagnosis, peaking at
a >4-fold higher rate in the year of diagnosis (RR
4.40 (4.04, 4.79)), and falling back to a 79% higher
rate (RR 1.79 (1.65, 1.94)) 6–10 years after diagnosis
(Table 3, Fig. 3, Additional file 1: Table S4). Fatigue
symptoms were recorded at a 7-fold higher rate (RR
6.93 (2.44, 19.7)) in cases compared with controls 6–
10 years pre-diagnosis, peaking at a 52-fold higher
rate (RR 51.6 (27.6, 96.5)), and falling back to an
almost 5-fold higher rate 6–10 years post-diagnosis
(RR 4.73 (2.47, 9.07)).
Variation in health care resource use by sex and
socioeconomic status
Women had higher rates of health care resource use
than men (Fig. 4). Case vs. control rate ratios tended to
be lower in female than in male patients (Table 4, Add-
itional file 1: Tables S5a, b), but the overall patterns of
relative health care resource use were similar (Fig. 4).
Practice-level IMD data were available for 78.5% (5266/
6710) and 85.8% (786/916) of adult and child patients,
respectively. Rates of health care resource use in the
upper three (least deprived) IMD quintiles were similar
to rates in the lower two quintiles, although rates of pre-
scriptions were higher in the bottom two quintiles
(Fig. 5). There was little discernible difference in relative
rates of health care resource use comparing cases vs.
controls between the two socioeconomic strata (Table 5,
Additional file 1: Tables S6a, b), although rate ratios for
tests and prescriptions were lower in the bottom two
than in the top three IMD quintiles in the pre-diagnosis
periods and in the year of diagnosis.
Table 1 Rates per patient year (95% CI) and rate ratios (95% CI) of GP consultations, tests, prescriptions and referrals from 15 years
before until 10 years after a first recorded diagnosis of CFS/ME in adult cases compared with controls
Year −15 to −11 Year −10 to −6 Year −5 to −1 Year 0 Year 1 to 5 Year 6 to 10
Total person years
Cases 4579 12,183 24,478 6710 25,447 10,815
Controls 4649 12,258 24,564 6710 25,038 10, 508
GP consultations
Cases (rate) 6.42 (6.35, 6.49) 6.77 (6.72, 6.81) 8.06 (8.02, 8.09) 10.6 (10.6, 10.7) 7.11 (7.08, 7.14) 6.59 (6.54, 6.64)
Controls (rate) 4.31 (4.25, 4.37) 4.53 (4.49, 4.56) 4.58 (4.56, 4.61) 4.29 (4.24, 4.34) 4.10 (4.07, 4.12) 4.24 (4.20, 4.28)
Rate ratio 1.49 (1.46, 1.52) 1.50 (1.48, 1.51) 1.76 (1.75, 1.77) 2.48 (2.44, 2.51) 1.73 (1.72, 1.75) 1.56 (1.54, 1.57)
Diagnostic tests
Cases (rate) 2.50 (2.46, 2.55) 8.01 (7.96, 8.06) 20.4 (20.3, 20.4) 37.0 (36.9, 37.2) 23.1 (23.0, 23.1) 26.4 (26.3, 26.5)
Controls (rate) 1.53 (1.49, 1.57) 4.98 (4.94, 5.02) 9.75 (9.71, 9.79) 12.3 (12.2, 12.3) 14.2 (14.1, 14.2) 17.6 (17.5, 17.7)
Rate ratio 1.64 (1.59, 1.68) 1.61 (1.59, 1.62) 2.09 (2.08, 2.10) 3.02 (3.00, 3.05) 1.63 (1.62, 1.64) 1.50 (1.49, 1.51)
Prescriptions
Cases (rate) 6.83 (6.76, 6.91) 6.26 (6.21, 6.30) 6.63 (6.60, 6.67) 7.84 (7.78, 7.91) 6.48 (6.45, 6.51) 6.63 (6.58, 6.68)
Controls (rate) 4.39 (4.33, 4.45) 3.84 (3.81, 3.88) 3.47 (3.45, 3.50) 3.34 (3.29, 3.38) 3.31 (3.29, 3.33) 3.59 (3.56, 3.63)
Rate ratio 1.56 (1.53, 1.58) 1.63 (1.61, 1.65) 1.91 (1.89, 1.93) 2.35 (2.31, 2.39) 1.96 (1.94, 1.98) 1.85 (1.82, 1.87)
Referrals
Cases (rate) 0.99 (0.96, 1.02) 0.86 (0.84, 0.87) 0.86 (0.85, 0.87) 1.38 (1.35, 1.41) 0.76 (0.75, 0.77) 0.71 (0.70, 0.73)
Controls (rate) 0.65 (0.63, 0.67) 0.55 (0.54, 0.57) 0.43 (0.42, 0.43) 0.39 (0.37, 0.40) 0.38 (0.37, 0.39) 0.40 (0.39, 0.41)
Rate ratio 1.53 (1.46, 1.60) 1.55 (1.50, 1.60) 2.02 (1.98, 2.07) 3.54 (3.39, 3.70) 2.00 (1.95, 2.05) 1.78 (1.72, 1.85)
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Discussion
Statement of principal findings
Our study has revealed three main features of long-term
patterns in health care resource use before and after a
diagnosis of CFS/ME: 1) adults and children diagnosed
with CFS/ME have greater health care needs than the
rest of the population for at least ten years before the
diagnosis; 2) from this higher baseline, there were steep
increases in use of health care resources 2–4 years be-
fore diagnosis in adults and 1–2 years before diagnosis
in children; and 3) a steep drop in resource use immedi-
ately after diagnosis was followed by sustained higher
levels of health care resource use for at least ten years
after diagnosis. These patterns were broadly similar in
women and men, and in social strata defined by IMD
quintiles, and were also seen in rates of symptoms gen-
erally and fatigue symptoms specifically.
The second of these three features was not unex-
pected. We had hypothesised that health care resource
use would increase from around the time of patient-
reported onset of illness, and the dramatic peaks in
health care resource use and symptoms are consistent
with CFS/ME being defined clinically as a disease of new
or distinct onset. However, the higher levels of health
needs and symptoms predating diagnosis by up to
15 years is a somewhat unexpected finding. It conflicts
with patients reporting that they were fit and well prior
to the onset of their illness [11, 12] (albeit in small quali-
tative studies), and it raises interesting questions about
the natural history of CFS/ME.
Our study in relation to other studies
In relation to onset of illness, seven case definitions for
CFS/ME have been used in clinical practice and research
since the first was published in 1988, and these defini-
tions have differed mainly in the minimum duration of
fatigue and the type and number of additional symptoms
[13]. That the fatigue must be of new or distinct onset
was a feature of the original CDC case definition [14],
and was also part of the Fukuda [15], Oxford [16], and
the (original) Canadian [17] case definition. The Canad-
ian criteria and its subsequent revision allowed for a
gradual onset, but recognised that onset was typically
distinct [18]. The recently-introduced US Institute of
Fig. 1 Rates of GP consultations, tests, prescriptions and referrals from 15 years before until 10 years after a first recorded diagnosis of CFS/ME in
adult cases compared with controls
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Medicine criteria for Systemic Exercise Intolerance Dis-
ease (SEID) require that the fatigue be “of new or defin-
ite onset (not lifelong)” [19], as do current UK National
Institute of Health and Care Excellence (NICE) clinical
guidelines [20].
The distinct peak in health care resource use that we
observed matches the duration of illness reported to cli-
nicians by patients when first assessed by specialist CFS/
ME services in England. For patients assessed during the
period 2004–2014, the median (IQR) duration of illness
for adult patients was 3 (1–8) years, and for adolescent
patients (who comprise the majority of child patients) it
was 1.5 (1 to 2) years [1]. The upper and lower bounds
of these IQR encompass the steep upward slope in
health care resource use in each patient group, i.e. the
rapid increase in health care needs is consistent with pa-
tients’ (or parents’) self-report of the time since onset.
However, the sustained higher use of health care re-
sources and numbers of symptoms predating this onset
is inconsistent with patients’ (or parents’) recollections
that they (or their child) had been healthy prior to the
onset of CFS/ME [11, 12], and conflicts somewhat with
case definitions worded to exclude fatigue that is lifelong
or not of new onset. There are several possible explana-
tions for this discrepancy.
Firstly, people may simply have had CFS/ME for a very
long time. The previously quoted durations of illness
(3 years for adults, 18 months for children) were self-
reported, and people with CFS/ME may be under-
estimating the length of time for which they have been ill.
Also, these are patients who access specialist services, who
will not include all patients with CFS/ME. CFS/ME may
begin as a mild form which develops quite suddenly into
more severe CFS/ME, thereby setting the patient on a
pathway to diagnosis. Patients’ (and parents’) recall of
their health status prior to the onset of more severe symp-
toms could be distorted by the debilitating nature of mod-
erate to severe CFS/ME, leading them to report having
been healthy. This is particularly plausible if the milder
form of CFS/ME had not prevented them from being in
full-time employment or had not led to notable absences
from school or college. We know that adults often perse-
vere in employment whilst coping with the symptoms of
CFS/ME for years before obtaining a diagnosis [2], and an
active case finding study in three secondary schools in
England led to 5% (23/461) of children whose attendance
was below 80% being diagnosed with CFS/ME, giving a
CFS/ME prevalence of 1% (28/2855) in the three schools
in the study [21]. Also, CFS/ME is accompanied by co-
morbidities including depression, anxiety, chronic pain,
migraine and irritable bowel disease [1], which can mask
CFS/ME as the primary disorder.
Secondly, it is possible that people who develop CFS/
ME have pre-existing risk factors which lead to higher
Table 2 Rates per patient year (95% CI) and rate ratios (95% CI) of GP consultations, tests, prescriptions and referrals from 10 years
before until 10 years after a first recorded diagnosis of CFS/ME in paediatric cases compared with controls
Year −10 to −6 Year −5 to −1 Year 0 Year 1 to 5 Year 6 to 10
Total person years
Cases 2088 3715 916 3290 1076
Controls 1996 3591 916 3257 1077
GP consultations
Cases (rate) 3.77 (3.69, 3.85) 4.43 (4.36, 4.49) 8.22 (8.04, 8.41) 4.42 (4.35, 4.49) 4.01 (3.89, 4.13)
Controls (rate) 2.59 (2.52, 2.66) 1.89 (1.84, 1.93) 2.01 (1.91, 2.10) 2.36 (2.31, 2.42) 2.47 (2.38, 2.57)
Rate ratio 1.45 (1.40, 1.51) 2.34 (2.28, 2.41) 4.10 (3.90, 4.31) 1.87 (1.82, 1.92) 1.62 (1.54, 1.70)
Diagnostic tests
Cases (rate) 1.42 (1.37, 1.47) 8.44 (8.35, 8.54) 29.4 (29.1, 29.8) 10.3 (10.2, 10.4) 11.8 (11.6, 12.0)
Controls (rate) 0.53 (0.49, 0.56) 1.21 (1.17, 1.24) 2.28 (2.19, 2.38) 3.90 (3.83, 3.97) 5.00 (4.87, 5.14)
Rate ratio 2.70 (2.51, 2.89) 7.01 (6.79, 7.23) 12.9 (12.3, 13.5) 2.64 (2.59, 2.70) 2.37 (2.29, 2.44)
Prescriptions
Cases (rate) 3.00 (2.93, 3.08) 3.37 (3.31, 3.43) 5.67 (5.52, 5.83) 3.83 (3.77, 3.90) 3.65 (3.54, 3.77)
Controls (rate) 2.08 (2.02, 2.14) 1.46 (1.42, 1.50) 1.71 (1.62, 1.79) 1.92 (1.88, 1.97) 1.99 (1.91, 2.07)
Rate ratio 1.44 (1.39, 1.50) 2.31 (2.23, 2.38) 3.33 (3.14, 3.52) 1.99 (1.93, 2.05) 1.84 (1.74, 1.93)
Referrals
Cases (rate) 0.25 (0.23, 0.27) 0.43 (0.41, 0.45) 1.28 (1.21, 1.35) 0.42 (0.40, 0.44) 0.39 (0.36, 0.43)
Controls (rate) 0.18 (0.16, 0.20) 0.14 (0.13, 0.15) 0.15 (0.12, 0.17) 0.16 (0.15, 0.17) 0.16 (0.13, 0.18)
Rate ratio 1.40 (1.22, 1.60) 3.08 (2.79, 3.41) 8.83 (7.38, 10.6) 2.61 (2.36, 2.89) 2.53 (2.12, 3.03)
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rates of health care resource use. Presentation for other
illnesses would be consistent with a subsequent diagno-
sis of CFS/ME if patients were generally more suscep-
tible to illness, e.g. immunologically or if patients with
CFS/ME have different health care seeking behaviour. A
small case–control study in England reported higher GP
consultation rates over three 5-year periods before a
diagnosis of CFS/ME, as we observed in our study [22].
The consultations were for a wide range of symptoms,
and the authors concluded that behaviour traits such as
disease conviction and somatic concern could not be
discounted as aetiological factors. Finally, it is possible
that patients who present repeatedly and regularly to
primary care are more likely to be given a diagnosis of
CFS/ME by their GP.
Relative rates of health care resource use and symptoms
6–10 years after diagnosis were not substantially different
from rate ratios 6–10 years before diagnosis, except
perhaps for lower relative rates of diagnostic tests and (in
child patients) fatigue symptoms, and higher relative rates
of prescriptions and referrals post-diagnosis. The overall
patterns in our study were similar to those observed in a
study of fibromyalgia using data from the General Practice
Research Database (GPRD, the precursor to CPRD) [23].
We are unable to determine from our data whether the
type of health care resource use by patients changes
following diagnosis, and we do not know how many
patients in our study received specialist treatment.
Receiving a diagnosis may change health care re-
source use, because patients have an identifiable ill-
ness which explains the fatigue and symptoms that
they have been experiencing and GPs may be able to
provide specific advice. Adult patients in England
have access to approximately 50 NHS specialist ser-
vices, many of which were established under the CFS/
ME Service Investment Programme (2004–2006) [24].
These services follow NICE guidance, including spe-
cific guidelines for diagnosis, specialist care, and on-
going management, with an overall patient-centred
approach to treatment [20]. Although outcomes up to
20 months after treatment are favourable for some
patients [25], long-term treatment outcomes for these
services have not been reported. Children have better
prognosis than adults [26], but specialist service
Fig. 2 Rates of GP consultations, tests, prescriptions and referrals from 10 years before until 10 years after a first recorded diagnosis of CFS/ME in
paediatric cases compared with controls
Collin et al. BMC Family Practice  (2017) 18:60 Page 7 of 13
provision for is much less comprehensive, with one
large paediatric service in the south west of England,
and patchy or non-existent provision elsewhere in the
UK.
Strengths and limitations
The main strength of our study is that it is based on
a large sample from a cohort of approximately four
million patients registered with a GP, representing ap-
proximately 7% of the population in the UK [5]. Pa-
tients have a median of 9.4 years (IQR 3.4-13.9) of
data [5], which gives us some (but not absolute) con-
fidence in classifying diagnoses as ‘new’ if the patient’s
medical record has no previously recorded diagnoses.
Two limitations of our study are that we do not
know how many cases of CFS/ME in the population
are undiagnosed or misdiagnosed, or what proportion
of CFS/ME cases in our study were correctly diag-
nosed. Although knowledge and awareness of CFS/
ME in primary care has improved over the past dec-
ade [27], some GPs still lack confidence in diagnosing
CFS/ME [28]. This is consistent with a relatively high
rate of misdiagnosis by GPs when referring to special-
ist services [29, 30]. The estimated incidence of adult
CFS/ME diagnoses in CPRD data in the period 2008–
2010 was broadly consistent with incidence estimated
from data obtained directly from NHS specialist CFS/
ME services in 2009, which gives some reassurance
that CFS/ME diagnoses recorded by GPs towards the
end of the period covered by our study were made or
confirmed by a specialist CFS/ME service [7]. How-
ever, CFS/ME diagnoses in CPRD data have yet to be
validated through linkage or other means.
Two other potential limitations of our study were that
people who contributed the longest durations of pre- and
post-diagnosis data may not have been representative of
CFS/ME patients and healthy controls, and that biases in
rate ratios could be introduced at the extremes of follow-
up if there were differential losses between the case–con-
trol pairs. However, there were no differential losses by
age, sex and IMD quintile, and sensitivity analyses re-
stricted to patients who had either 10 years of pre-
diagnosis or 10 years of post-diagnosis data yielded rate
ratios which were similar to those in our main analysis.
Unanswered questions and future research
The extent to which the elevated health care needs
of adults and children who were subsequently
Table 3 Rates (95% CI) of all symptoms and of fatigue symptoms and rate ratios (95% CI) from 15 years before (adults) or 10 years
before (paediatric) until 10 years after a first recorded diagnosis of CFS/ME
Year −15 to −11 Year −10 to −6 Year −5 to −1 Year 0 Year 1 to 5 Year 6 to 10
Total adult person years
Cases 4579 12,183 24,478 6710 25,447 10,815
Controls 4649 12,258 24,564 6710 25,038 10, 508
Adults (all symptoms)
Cases (rate per patient year) 1.14 (1.11, 1.17) 1.53 (1.51, 1.55) 2.46 (2.44, 2.48) 3.19 (3.15, 3.23) 2.35 (2.33, 2.37) 2.40 (2.37, 2.43)
Controls (rate per patient year) 0.67 (0.65, 0.70) 0.98 (0.96, 1.00) 1.30 (1.29, 1.32) 1.36 (1.34, 1.39) 1.41 (1.40, 1.43) 1.55 (1.53, 1.57)
Rate ratio 1.69 (1.62, 1.77) 1.57 (1.53, 1.60) 1.89 (1.87, 1.92) 2.34 (2.28, 2.39) 1.67 (1.65, 1.69) 1.55 (1.52, 1.58)
Adults (fatigue symptoms)
Cases (rate per patient year) 2.80 (2.31, 3.28) 6.15 (5.71, 6.59) 19.4 (18.9, 20.0) 57.5 (55.7, 59.3) 10.9 (10.5, 11.3) 8.61 (8.06, 9.16)
Controls (rate per patient year) 0.34 (0.18, 0.51) 1.61 (1.38, 1.83) 2.31 (2.12, 2.50) 2.62 (2.24, 3.01) 2.66 (2.45, 2.86) 2.29 (2.00, 2.58)
Rate ratio 8.12 (4.83, 13.7) 3.83 (3.27, 4.48) 8.40 (7.70, 9.16) 21.9 (18.8, 25.5) 4.10 (3.77, 4.46) 3.75 (3.26, 4.32)
Total paediatric person years
Cases 2088 3715 916 3290 1076
Controls 1996 3591 916 3257 1077
Paediatric (all symptoms)
Cases (rate per 100 patient years) 1.14 (1.10, 1.19) 1.74 (1.70, 1.78) 3.12 (3.01, 3.24) 1.62 (1.58, 1.66) 1.53 (1.46, 1.61)
Controls (rate per 100 patient years) 0.68 (0.64, 0.72) 0.67 (0.64, 0.69) 0.71 (0.66, 0.76) 0.81 (0.78, 0.84) 0.86 (0.80, 0.91)
Rate ratio 1.68 (1.57, 1.79) 2.60 (2.48, 2.73) 4.40 (4.04, 4.79) 2.00 (1.91, 2.10) 1.79 (1.65, 1.94)
Paediatric (fatigue symptoms)
Cases (rate per 100 patient years) 1.39 (0.88, 1.89) 11.6 (10.5, 12.7) 56.3 (51.5, 61.2) 7.36 (6.43, 8.28) 4.83 (3.52, 6.15)
Controls (rate per 100 patient years) 0.20 (0.00, 0.40) 0.56 (0.31, 0.80) 1.09 (0.42, 1.77) 1.81 (1.35, 2.27) 1.02 (0.42, 1.62)
Rate ratio 6.93 (2.44, 19.7) 20.8 (13.3, 32.6) 51.6 (27.6, 96.5) 4.06 (3.05, 5.40) 4.73 (2.47, 9.07)
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diagnosed with CFS/ME reflect long-term und-
iagnosed illness requires further investigation. Ideally
this would be accomplished by means of a large
long-term prospective cohort study with deep
phenotyping of participants, including repeated mea-
surements of symptoms, biological markers, psycho-
logical states, and objective measures of health and
function. The sample size for such studies could be
reduced by following patients who have an acute in-
fectious illness, given that CFS/ME will be triggered
in a fairly constant proportion of patients [31]. How-
ever, these patients will not represent all patients
who develop CFS/ME if the illness is triggered by
other events. Electronic primary care records can be
used to investigate whether specific illnesses occur
more frequently in patients who are subsequently di-
agnosed with CFS/ME [32], and to investigate what
the overall higher rates of health care resource use
actually represent, in terms of specific tests, pre-
scriptions, and referrals. With regard to post-
diagnosis health care resource use, cohort studies are
needed to quantify long-term treatment outcomes
among patients who are treated by specialist CFS/
ME services after diagnosis. Qualitative methods could be
used to investigate how health care needs before and after
diagnosis relate to patients’ health status and quality
of life.
Conclusions
We cannot discount the possibility that patients in
our study have presented over a period of 10 or
more years with symptoms related to CFS/ME, even
if a very long prodromal period before the onset of
CFS/ME appears to be inconsistent with patients’
own reports of when their illness began and with pa-
tients describing themselves as being fit and healthy
prior to onset. We are also mindful of the known
heterogeneity within CFS/ME, and that patterns of
health care resource use could vary substantially
across different CFS/ME phenotypes. Diagnosis of
CFS/ME coincided with a dramatic peak in health
care resource use, and had little or no impact on
health resource use in the longer term.
Fig. 3 Rates of all symptoms and fatigue symptoms from 15 years before (adults) or 10 years before (paediatric) until 10 years after a first
recorded diagnosis of CFS/ME in cases compared with controls
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Fig. 4 Rates of GP consultations, tests, prescriptions and referrals from 10 years before until 10 years after a first recorded diagnosis of CFS/ME in
adult cases compared with controls by sex
Table 4 Rate ratios (95% CI) of GP consultations, tests, prescriptions and referrals from 10 years before until 10 years after a first
recorded diagnosis of CFS/ME in adult cases compared with controls by sex
Year −10 to −6 Year −5 to −1 Year 0 Year 1 to 5 Year 6 to 10
Year −10 to −6 Year −5 to −1 Year 0 Year 1 to 5 Year 6 to 10
GP consultations
Female 1.47 (1.45, 1.49) 1.70 (1.69, 1.71) 2.35 (2.31, 2.38) 1.68 (1.66, 1.69) 1.52 (1.50, 1.54)
Male 1.56 (1.53, 1.60) 1.99 (1.96, 2.02) 2.98 (2.90, 3.07) 1.95 (1.92, 1.99) 1.69 (1.65, 1.74)
Diagnostic tests
Female 1.60 (1.58, 1.62) 2.01 (2.00, 2.02) 2.87 (2.85, 2.90) 1.58 (1.57, 1.59) 1.51 (1.50, 1.52)
Male 1.61 (1.58, 1.65) 2.39 (2.37, 2.42) 3.56 (3.50, 3.61) 1.80 (1.79, 1.82) 1.49 (1.47, 1.51)
Prescriptions
Female 1.63 (1.61, 1.65) 1.87 (1.85, 1.89) 2.30 (2.26, 2.34) 1.93 (1.91, 1.95) 1.79 (1.77, 1.82)
Male 1.55 (1.51, 1.60) 2.07 (2.03, 2.11) 2.56 (2.47, 2.65) 2.07 (2.03, 2.11) 2.08 (2.03, 2.14)
Referrals
Female 1.49 (1.44, 1.54) 1.95 (1.90, 2.00) 3.34 (3.18, 3.50) 1.95 (1.89, 2.00) 1.78 (1.71, 1.86)
Male 1.77 (1.65, 1.90) 2.30 (2.18, 2.41) 4.32 (3.93, 4.73) 2.18 (2.07, 2.30) 1.80 (1.67, 1.95)
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Fig. 5 Rates of GP consultations, tests, prescriptions and referrals from 10 years before until 10 years after a first recorded diagnosis of CFS/ME in
adult cases compared with controls by Index of Multiple Deprivation (IMD) quintiles
Table 5 Rate ratios (95% CI) of GP consultations, tests, prescriptions and referrals from 10 years before until 10 years after a first
recorded diagnosis of CFS/ME in adult cases compared with controls by Index of Multiple Deprivation (IMD) quintiles
Year −10 to −6 Year −5 to −1 Year 0 Year 1 to 5 Year 6 to 10
GP consultations
Top 3 quintiles 1.58 (1.55, 1.60) 1.75 (1.73, 1.77) 2.52 (2.47, 2.57) 1.75 (1.73, 1.76) 1.52 (1.50, 1.55)
Bottom 2 quintiles 1.40 (1.37, 1.43) 1.77 (1.75, 1.80) 2.49 (2.42, 2.56) 1.78 (1.76, 1.81) 1.70 (1.66, 1.75)
Diagnostic tests
Top 3 quintiles 1.78 (1.76, 1.81) 2.20 (2.19, 2.22) 3.30 (3.27, 3.34) 1.69 (1.68, 1.70) 1.48 (1.46, 1.49)
Bottom 2 quintiles 1.39 (1.37, 1.42) 2.02 (2.00, 2.03) 2.80 (2.76, 2.84) 1.69 (1.68, 1.71) 1.68 (1.66, 1.71)
Prescriptions
Top 3 quintiles 1.81 (1.78, 1.85) 1.92 (1.89, 1.94) 2.43 (2.38, 2.49) 2.00 (1.97, 2.02) 1.90 (1.86, 1.93)
Bottom 2 quintiles 1.50 (1.47, 1.53) 1.85 (1.82, 1.88) 2.23 (2.16, 2.30) 1.93 (1.90, 1.96) 2.07 (2.01, 2.13)
Referrals
Top 3 quintiles 1.59 (1.52, 1.66) 2.02 (1.95, 2.09) 3.64 (3.43, 3.86) 2.03 (1.97, 2.10) 1.78 (1.69, 1.87)
Bottom 2 quintiles 1.45 (1.38, 1.53) 1.97 (1.88, 2.05) 3.53 (3.25, 3.84) 1.95 (1.86, 2.05) 1.84 (1.69, 1.99)
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